Submit Search
Upload
Les Aia Stanford And Effect Of Valuation 09 Nov11
•
Download as PPT, PDF
•
1 like
•
201 views
Gary M. Myles, Ph.D.
Follow
Report
Share
Report
Share
1 of 54
Download now
Recommended
This patent law seminar discusses changes in inequitable conduct doctrine after McKesson v. Bridge Medical and patentable subject matter, particularly in biotechnology inventions, after In re Bilski
McKesson and Bilski
McKesson and Bilski
Gary M. Myles, Ph.D.
This article discusses changes in the patent law obviousness doctrine after KSR and provides strategy recommendations for protecting biotechnology inventions
Post-KSR Obviousness
Post-KSR Obviousness
Gary M. Myles, Ph.D.
Test
Test
rsubs2009
This presentation addresses the why, what, and how to protect inventions from the vantage point of the early-stage, pre-financing, start-up company that is interested in patenting its inventions and developing an intellectual property portfolio that maximizes the company's valuation and sets it up for success during the intellectual property due diligence that accompanies financing rounds, corporate partnerships, commercialization, and merger and acquisition.
Protecting the Inventions of Start-ups
Protecting the Inventions of Start-ups
Gary M. Myles, Ph.D.
This Merchant & Gould whitepaper summarizes the holding of the recent Supreme Court Association of Molecular Pathology v. Myriad Genetics decision, outlines its impact, and provides practice tips to those endeavoring to protect nucleic acids, genes, cDNAs, and other biological molecules, including proteins and antibodies as well as diagnostic methods that relate to laws and products of nature.
Merchant & Gould Whitepaper: Association of Molecular Pathology v. Myriad Ge...
Merchant & Gould Whitepaper: Association of Molecular Pathology v. Myriad Ge...
Gary M. Myles, Ph.D.
CASRIP 2012 -- Patenting of Human DNA and Embryos
CASRIP 2012 -- Patenting of Human DNA and Embryos
Gary M. Myles, Ph.D.
This presentation discusses the patent application disclosure requirements under 35 U.S.C. Section 112 and relates, in particular, to the Supreme Court and Federal Circuit case law relevant to patent specifications and claims protecting inventions in the life sciences, biotechnology, and pharmaceutical industries
2020 01-28 uwls-apl_biotech_disclosure under 35_usc112
2020 01-28 uwls-apl_biotech_disclosure under 35_usc112
Gary M. Myles, Ph.D.
Amicus Brief submitted by BIO (Biotechnology Industry Organization) to Supreme Court of the United States in Commil USA, LLC v. Cisco Systems (No. 13-896)
Commil v. Cisco: Brief of Biotechnology Industry Organization as Amicus Curi...
Commil v. Cisco: Brief of Biotechnology Industry Organization as Amicus Curi...
Gary M. Myles, Ph.D.
Recommended
This patent law seminar discusses changes in inequitable conduct doctrine after McKesson v. Bridge Medical and patentable subject matter, particularly in biotechnology inventions, after In re Bilski
McKesson and Bilski
McKesson and Bilski
Gary M. Myles, Ph.D.
This article discusses changes in the patent law obviousness doctrine after KSR and provides strategy recommendations for protecting biotechnology inventions
Post-KSR Obviousness
Post-KSR Obviousness
Gary M. Myles, Ph.D.
Test
Test
rsubs2009
This presentation addresses the why, what, and how to protect inventions from the vantage point of the early-stage, pre-financing, start-up company that is interested in patenting its inventions and developing an intellectual property portfolio that maximizes the company's valuation and sets it up for success during the intellectual property due diligence that accompanies financing rounds, corporate partnerships, commercialization, and merger and acquisition.
Protecting the Inventions of Start-ups
Protecting the Inventions of Start-ups
Gary M. Myles, Ph.D.
This Merchant & Gould whitepaper summarizes the holding of the recent Supreme Court Association of Molecular Pathology v. Myriad Genetics decision, outlines its impact, and provides practice tips to those endeavoring to protect nucleic acids, genes, cDNAs, and other biological molecules, including proteins and antibodies as well as diagnostic methods that relate to laws and products of nature.
Merchant & Gould Whitepaper: Association of Molecular Pathology v. Myriad Ge...
Merchant & Gould Whitepaper: Association of Molecular Pathology v. Myriad Ge...
Gary M. Myles, Ph.D.
CASRIP 2012 -- Patenting of Human DNA and Embryos
CASRIP 2012 -- Patenting of Human DNA and Embryos
Gary M. Myles, Ph.D.
This presentation discusses the patent application disclosure requirements under 35 U.S.C. Section 112 and relates, in particular, to the Supreme Court and Federal Circuit case law relevant to patent specifications and claims protecting inventions in the life sciences, biotechnology, and pharmaceutical industries
2020 01-28 uwls-apl_biotech_disclosure under 35_usc112
2020 01-28 uwls-apl_biotech_disclosure under 35_usc112
Gary M. Myles, Ph.D.
Amicus Brief submitted by BIO (Biotechnology Industry Organization) to Supreme Court of the United States in Commil USA, LLC v. Cisco Systems (No. 13-896)
Commil v. Cisco: Brief of Biotechnology Industry Organization as Amicus Curi...
Commil v. Cisco: Brief of Biotechnology Industry Organization as Amicus Curi...
Gary M. Myles, Ph.D.
The Court found that separating the DNA of a gene from its surrounding genetic material, even though time consuming and valuable, is not an invention.
Myriad Decision May Invalidate Many Patents
Myriad Decision May Invalidate Many Patents
Gary M. Myles, Ph.D.
COMMIL v. CISCO_Brief of Biotechnology Industry Organization (BIO) as Amicus Curiae in Support of Petitioner
COMMIL v. CISCO_Brief of Biotechnology Industry Organization (BIO) as Amicus ...
COMMIL v. CISCO_Brief of Biotechnology Industry Organization (BIO) as Amicus ...
Gary M. Myles, Ph.D.
Biotechnology Patents: Utility and eligibility requirements under 35 USC 101. This presentation follows the historical development of the utility requirement from the early 19th century case Lowell v. Lewis (MA 1817), the origin of the specific, substantial, and credible standard for a patent disclosure from Brenner v. Manson (SCOTUS 1966), and the modern application of the Brenner standard for biotechnology patents in In re Fisher (Fed. Cir. 2005). Biotechnology eligibility requirements are discussed from the early Supreme Court case Funk Brothers v. Kalo, the seminal biotechnology Supreme Court case Diamond v. Chakrabarty (SCOTUS 1980) where the court holds that statutory subject matter includes "anything under the sun that is made by man," through the recent Supreme Court decision in Myriad v. ACLU (SCOTUS 2013) where the court held that diagnostic method claims and nucleic acid claims that read on products of nature are patent inelibible. Practice tips are provided to ensure that patent claims avoid the exceptions of 35 USC 101 and withstand scrutiny during litigation and business transactions, such as licensing.
2017 02-15 uwls-apl_biotech 101
2017 02-15 uwls-apl_biotech 101
Gary M. Myles, Ph.D.
Biotechnology Patents: Disclosure Requirements under 35 USC 112. Discusses case law development of the enablement and written description requirements from In re Wright (Fed. Cir. 1993) through Ariad Pharmaceuticals v. Eli Lilly (Fed. Cir. 2010), including the origin of the "super enablement" requirement in Regents of the University of California v. Eli Lilly (Fed. Cir. 1997), the thought provoking dissent by Chief Judge Rader in Enzo Biochem v. Gen-Probe (Fed. Cir. 2002), the paradoxical "nascent technology" holding in Chiron v. Genentech (Fed. Cir. 2004), and the risks of relying on functional claim language from Rochester v. Searle (Fed. Cir. 2004). Practice tips are provided for avoiding the pitfalls in patent and claim drafting in view of these seminal cases.
2017 01-25 uwls-apl_biotech 112
2017 01-25 uwls-apl_biotech 112
Gary M. Myles, Ph.D.
This presentation discusses the key factors that are important in selecting an appropriate corporate entity for a startup company
2015-11-4_WSU_Defining a Corporate Structure for a Startup Company
2015-11-4_WSU_Defining a Corporate Structure for a Startup Company
Gary M. Myles, Ph.D.
2015-11-4_WSU_Corp Structure & Formation for Start-ups
2015-11-4_WSU_Corp Structure & Formation for Start-ups
Gary M. Myles, Ph.D.
Gary's Ph.D. adviser, Aziz Sancar, is awarded the Nobel Prize in Chemistry for his work ion nucleotide excision repair.
Aziz Sancar 2015 Nobel Prize in Chemistry
Aziz Sancar 2015 Nobel Prize in Chemistry
Gary M. Myles, Ph.D.
13-896; tsac; Biotechnology Industry Organization
13-896; tsac; Biotechnology Industry Organization
Gary M. Myles, Ph.D.
Preparing for a Financial Audit & Corporate Due Diligence
Preparing for a Financial Audit & Corporate Due Diligence
Gary M. Myles, Ph.D.
This resume provides a summary of Gary Myles legal and scientific background, education, publications, presentations, board memberships, and honors.
Gary M. Myles, J.D., Ph.D. -- Biotechnology, Life Sciences, and Pharmaceutica...
Gary M. Myles, J.D., Ph.D. -- Biotechnology, Life Sciences, and Pharmaceutica...
Gary M. Myles, Ph.D.
America Invents Act: Recent Changes to US Patent Law and Practice
America Invents Act: Recent Changes to US Patent Law and Practice
Gary M. Myles, Ph.D.
This presentation discusses the historical context for the recent court decisions that affect the patent eligibility of biotechnology inventions, including those directed to genes, cDNAs, proteins, antibodies, and diagnostic methods. Discussed are the early Funk Brothers and Chakrabarty decisions as well as the Lab Corp, Bilski, Prometheus, Classen, and Myriad court opinions. The impact of the court holdings on the future development of biotechnology inventions, in particular personalized medicine inventions, is analyzed as is the erosion of the requisite incentives of innovative companies to invent and commercialize in areas where patent protection is less certain.
Biotechnology Patent Eligibility
Biotechnology Patent Eligibility
Gary M. Myles, Ph.D.
Patenting In The Biotech Industry 21 Sep10
Patenting In The Biotech Industry 21 Sep10
Gary M. Myles, Ph.D.
Biotechnology Novelty And Nonobviousness 14 Sep10
Biotechnology Novelty And Nonobviousness 14 Sep10
Gary M. Myles, Ph.D.
Biotechnology Enablement And Written Description 28 Sep10
Biotechnology Enablement And Written Description 28 Sep10
Gary M. Myles, Ph.D.
Career Options Life Scientist 04Jun10
Career Options Life Scientist 04Jun10
Gary M. Myles, Ph.D.
Biotechnology Written Description, Enablement, and Patent Eligibility
Biotechnology Written Description, Enablement, and Patent Eligibility
Gary M. Myles, Ph.D.
More Related Content
More from Gary M. Myles, Ph.D.
The Court found that separating the DNA of a gene from its surrounding genetic material, even though time consuming and valuable, is not an invention.
Myriad Decision May Invalidate Many Patents
Myriad Decision May Invalidate Many Patents
Gary M. Myles, Ph.D.
COMMIL v. CISCO_Brief of Biotechnology Industry Organization (BIO) as Amicus Curiae in Support of Petitioner
COMMIL v. CISCO_Brief of Biotechnology Industry Organization (BIO) as Amicus ...
COMMIL v. CISCO_Brief of Biotechnology Industry Organization (BIO) as Amicus ...
Gary M. Myles, Ph.D.
Biotechnology Patents: Utility and eligibility requirements under 35 USC 101. This presentation follows the historical development of the utility requirement from the early 19th century case Lowell v. Lewis (MA 1817), the origin of the specific, substantial, and credible standard for a patent disclosure from Brenner v. Manson (SCOTUS 1966), and the modern application of the Brenner standard for biotechnology patents in In re Fisher (Fed. Cir. 2005). Biotechnology eligibility requirements are discussed from the early Supreme Court case Funk Brothers v. Kalo, the seminal biotechnology Supreme Court case Diamond v. Chakrabarty (SCOTUS 1980) where the court holds that statutory subject matter includes "anything under the sun that is made by man," through the recent Supreme Court decision in Myriad v. ACLU (SCOTUS 2013) where the court held that diagnostic method claims and nucleic acid claims that read on products of nature are patent inelibible. Practice tips are provided to ensure that patent claims avoid the exceptions of 35 USC 101 and withstand scrutiny during litigation and business transactions, such as licensing.
2017 02-15 uwls-apl_biotech 101
2017 02-15 uwls-apl_biotech 101
Gary M. Myles, Ph.D.
Biotechnology Patents: Disclosure Requirements under 35 USC 112. Discusses case law development of the enablement and written description requirements from In re Wright (Fed. Cir. 1993) through Ariad Pharmaceuticals v. Eli Lilly (Fed. Cir. 2010), including the origin of the "super enablement" requirement in Regents of the University of California v. Eli Lilly (Fed. Cir. 1997), the thought provoking dissent by Chief Judge Rader in Enzo Biochem v. Gen-Probe (Fed. Cir. 2002), the paradoxical "nascent technology" holding in Chiron v. Genentech (Fed. Cir. 2004), and the risks of relying on functional claim language from Rochester v. Searle (Fed. Cir. 2004). Practice tips are provided for avoiding the pitfalls in patent and claim drafting in view of these seminal cases.
2017 01-25 uwls-apl_biotech 112
2017 01-25 uwls-apl_biotech 112
Gary M. Myles, Ph.D.
This presentation discusses the key factors that are important in selecting an appropriate corporate entity for a startup company
2015-11-4_WSU_Defining a Corporate Structure for a Startup Company
2015-11-4_WSU_Defining a Corporate Structure for a Startup Company
Gary M. Myles, Ph.D.
2015-11-4_WSU_Corp Structure & Formation for Start-ups
2015-11-4_WSU_Corp Structure & Formation for Start-ups
Gary M. Myles, Ph.D.
Gary's Ph.D. adviser, Aziz Sancar, is awarded the Nobel Prize in Chemistry for his work ion nucleotide excision repair.
Aziz Sancar 2015 Nobel Prize in Chemistry
Aziz Sancar 2015 Nobel Prize in Chemistry
Gary M. Myles, Ph.D.
13-896; tsac; Biotechnology Industry Organization
13-896; tsac; Biotechnology Industry Organization
Gary M. Myles, Ph.D.
Preparing for a Financial Audit & Corporate Due Diligence
Preparing for a Financial Audit & Corporate Due Diligence
Gary M. Myles, Ph.D.
This resume provides a summary of Gary Myles legal and scientific background, education, publications, presentations, board memberships, and honors.
Gary M. Myles, J.D., Ph.D. -- Biotechnology, Life Sciences, and Pharmaceutica...
Gary M. Myles, J.D., Ph.D. -- Biotechnology, Life Sciences, and Pharmaceutica...
Gary M. Myles, Ph.D.
America Invents Act: Recent Changes to US Patent Law and Practice
America Invents Act: Recent Changes to US Patent Law and Practice
Gary M. Myles, Ph.D.
This presentation discusses the historical context for the recent court decisions that affect the patent eligibility of biotechnology inventions, including those directed to genes, cDNAs, proteins, antibodies, and diagnostic methods. Discussed are the early Funk Brothers and Chakrabarty decisions as well as the Lab Corp, Bilski, Prometheus, Classen, and Myriad court opinions. The impact of the court holdings on the future development of biotechnology inventions, in particular personalized medicine inventions, is analyzed as is the erosion of the requisite incentives of innovative companies to invent and commercialize in areas where patent protection is less certain.
Biotechnology Patent Eligibility
Biotechnology Patent Eligibility
Gary M. Myles, Ph.D.
Patenting In The Biotech Industry 21 Sep10
Patenting In The Biotech Industry 21 Sep10
Gary M. Myles, Ph.D.
Biotechnology Novelty And Nonobviousness 14 Sep10
Biotechnology Novelty And Nonobviousness 14 Sep10
Gary M. Myles, Ph.D.
Biotechnology Enablement And Written Description 28 Sep10
Biotechnology Enablement And Written Description 28 Sep10
Gary M. Myles, Ph.D.
Career Options Life Scientist 04Jun10
Career Options Life Scientist 04Jun10
Gary M. Myles, Ph.D.
Biotechnology Written Description, Enablement, and Patent Eligibility
Biotechnology Written Description, Enablement, and Patent Eligibility
Gary M. Myles, Ph.D.
More from Gary M. Myles, Ph.D.
(17)
Myriad Decision May Invalidate Many Patents
Myriad Decision May Invalidate Many Patents
COMMIL v. CISCO_Brief of Biotechnology Industry Organization (BIO) as Amicus ...
COMMIL v. CISCO_Brief of Biotechnology Industry Organization (BIO) as Amicus ...
2017 02-15 uwls-apl_biotech 101
2017 02-15 uwls-apl_biotech 101
2017 01-25 uwls-apl_biotech 112
2017 01-25 uwls-apl_biotech 112
2015-11-4_WSU_Defining a Corporate Structure for a Startup Company
2015-11-4_WSU_Defining a Corporate Structure for a Startup Company
2015-11-4_WSU_Corp Structure & Formation for Start-ups
2015-11-4_WSU_Corp Structure & Formation for Start-ups
Aziz Sancar 2015 Nobel Prize in Chemistry
Aziz Sancar 2015 Nobel Prize in Chemistry
13-896; tsac; Biotechnology Industry Organization
13-896; tsac; Biotechnology Industry Organization
Preparing for a Financial Audit & Corporate Due Diligence
Preparing for a Financial Audit & Corporate Due Diligence
Gary M. Myles, J.D., Ph.D. -- Biotechnology, Life Sciences, and Pharmaceutica...
Gary M. Myles, J.D., Ph.D. -- Biotechnology, Life Sciences, and Pharmaceutica...
America Invents Act: Recent Changes to US Patent Law and Practice
America Invents Act: Recent Changes to US Patent Law and Practice
Biotechnology Patent Eligibility
Biotechnology Patent Eligibility
Patenting In The Biotech Industry 21 Sep10
Patenting In The Biotech Industry 21 Sep10
Biotechnology Novelty And Nonobviousness 14 Sep10
Biotechnology Novelty And Nonobviousness 14 Sep10
Biotechnology Enablement And Written Description 28 Sep10
Biotechnology Enablement And Written Description 28 Sep10
Career Options Life Scientist 04Jun10
Career Options Life Scientist 04Jun10
Biotechnology Written Description, Enablement, and Patent Eligibility
Biotechnology Written Description, Enablement, and Patent Eligibility
Download now
